Different exosomal microRNA profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders by Chen, C. et al.
ORIGINAL RESEARCH
published: 29 May 2020
doi: 10.3389/fimmu.2020.01064
Frontiers in Immunology | www.frontiersin.org 1 May 2020 | Volume 11 | Article 1064
Edited by:
Robert Weissert,













†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Multiple Sclerosis and
Neuroimmunology,
a section of the journal
Frontiers in Immunology
Received: 14 December 2019
Accepted: 04 May 2020
Published: 29 May 2020
Citation:
Chen C, Wu Y, Li M, Cui C, Zhao Y,
Sun X, Wang Y, Liu C, Wu H, Zhong X,
Kermode AG, Peng L and Qiu W
(2020) Different Exosomal microRNA





Different Exosomal microRNA Profile
in Aquaporin-4 Antibody Positive
Neuromyelitis Optica Spectrum
Disorders
Chen Chen 1†, Yunting Wu 1†, Miaochang Li 2, Chunping Cui 1, Yipeng Zhao 1, Xiaobo Sun 1,
Yuge Wang 1, Chunxin Liu 1, Haotian Wu 1, Xiaonan Zhong 1, Allan G. Kermode 1,3,4,5,
Lisheng Peng 1* and Wei Qiu 1*
1Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2Department of
Neurology, Zhaoqing No. 1 People’s Hospital, Zhaoqing, China, 3Centre for Neuromuscular and Neurological Disorders,
University of Western Australia, Perth, WA, Australia, 4Department of Neurology, Sir Charles Gairdner Hospital, Queen
Elizabeth II Medical Centre, Perth, WA, Australia, 5 Institute of Immunology and Infectious Diseases, Murdoch University,
Perth, WA, Australia
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are
inflammatory demyelinating diseases of the central nervous system. Exosomal
microRNAs (miRNAs) are emerging biomarkers for demyelinating diseases. In this
study, 52 aquaporin-4 antibody serum-positive NMOSD patients, 18 relapsing-remitting
multiple sclerosis (RRMS) patients and 17 healthy controls (HCs) were included for the
next-generation sequencing (NGS). To validate the NGS results, the valuable miRNAs
were selected for validation by real-time quantitative polymerase chain reaction in
another cohort of patients, comprising 31 NMOSD patients and 14 HCs. In addition,
these miRNAs were also validated in a longitudinal study. NGS data revealed the
exosomal miRNAs profile in NMOSD patients was different from HCs. Among those
potential exosomal miRNAs which can distinguish NMOSD status, hsa-miR-122-3p
and hsa-miR-200a-5p were the most abundant miRNAs. In addition, hsa-miR-122-3p
and hsa-miR-200a-5p were significantly upregulated in the serum exosome of
relapsing NMOSD compared with that in remitting NMOSD. Hsa-miR-122-3p and
hsa-miR-200a-5p had positive correlations with disease severity in NMOSD patients.
Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that the MAPK,
Wnt and Ras signaling pathways were enriched. Further biological function analysis
demonstrated that these two miRNAs might be involved in the immunoregulation of
NMOSD pathogenesis. Our results indicated that miRNAs delivered by exosomes could
be applied as potential biomarkers for NMOSD.
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INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are inflammatory
demyelinating diseases in the central nervous system (CNS) with different pathogeneses.
Immunoglobulin G antibody against aquaporin-4 (AQP4-IgG) is considered a highly specific
biomarker and is present in more than 80% of NMOSD patients (1). AQP4-IgG targets
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aquaporin-4, inducing astrocytic damage by antibody-dependent
cellular cytotoxicity mechanisms (2), and inducing the non-
AQP4-expressing cells damage by antibody-dependent cellular
cytotoxicity bystander killing mechanism (3). Although AQP4-
IgG is widely recognized as the pathogenic factor of NMOSD,
other mechanisms that may be involved are still worth studying.
microRNAs (miRNAs) are a class of short non-coding RNAs
that are ∼18 to 25 nucleotides in length. miRNAs perform
vital biological functions and can be novel diagnostic and
prognostic biomarkers in clinical practice. A recent study using
next-generation sequencing (NGS) demonstrated that circulating
miRNAs in NMOSD may permit its discrimination from MS
(4). Exosomes are 30–120 nm membraned nanovesicles that are
formed in the cytoplasm and secreted by virtually all cell types.
Exosomes differ based on the cell of origin and are relatively
easily detected in serum and other biological fluids (5). A
recent study has demonstrated that exosomal protein spectrum
changed after the plasma exchange in NMOSD patients and
a series of complement components possibly associates with
the pathogenesis of NMOSD (6). The biological functions of
exosomes also rely on their cargos, such as miRNAs, long non-
coding RNAs. miRNAs delivered by exosomes has already been
found to play important roles in intercellular communication
(7). A recent study demonstrated that relapsing-remitting MS
(RRMS) patients exhibited altered exosomal miRNAs profile (8).
However, serum exosomal miRNAs profiles have not yet been
investigated in NMOSD, and the potential role in differentiating
NMOSD fromMS has not yet been explored.
MATERIALS AND METHODS
Subjects
This study consecutively recruited 52 AQP4-IgG-positive
NMOSD patients (17 in acute phase and 35 in remission), 18
RRMS patients (6 in acute phase and 12 in remission) and
17 healthy controls (HCs) for the NGS study, and another
independent group of 31 NMOSD patients (16 in the acute
phase and 15 in remission) and 14 HCs for the real-time
quantitative polymerase chain reaction (RT-qPCR) validation
of potential miRNAs. In addition, a longitudinal study was
conducted to validate the different expressions of valuable
miRNAs between acute phase and remission in the same patients
(7 AQP4-IgG-positive NMOSD patients) by RT-qPCR. All the
participants were recruited at the Third Affiliated Hospital of
Sun Yat-Sen University from March 2017 to September 2018.
To reduce inhomogeneity of NMOSD group, only AQP4-IgG
positive NMOSD patients were included. All the NMOSD and
MS patients meet the international panel diagnosis criteria for
NMOSD and MS (9, 10). MS patients also meet the typical
Barkhoff MRI criteria, and patients with atypical MRI features
were excluded (11). HCs were selected after clinical examination
and none of them had nervous system diseases. The clinical
relapse was defined as an acute appearance of new symptoms
lasting for at least 24 h, with new T2 lesions or enhanced T1
lesions on magnetic resonance imaging (MRI) and an increase
in the expanded disability status scale (EDSS) score of over
1.0. The remission phase was defined as a period when the
neurological condition of the patient had been stable for more
than one month.
This study was approved by the ethics committee of the Third
Affiliated Hospital of Sun Yat-Sen University. Informed written
consent was obtained from all participants.
Sample Collection and Antibody Testing
Blood were harvested from all participants after fasting for at
least 4 h. All NMOSD patients were AQP4-IgG positive, whileMS
patients were negative. In addition, all participants were myelin
oligodendrocyte glycoprotein (MOG) antibody negative. Blood
was collected from patients in the acute stage before clinical
treatment. Blood samples were stored at 4◦C for 4 h to allow
clotting. Then, samples were centrifuged at 2500 × g for 10min
at 4◦C. Isolated serum (∼4 milliliters) was preserved at −80◦C
for further analysis.
Serum immunoglobulin G antibody against MOG was tested
by an in-house cell-based assay using live cells transfected
with full-length human MOG. AQP4-IgG was detected
using an indirect immunofluorescence assay (EUROIMMUN
Medizinische Labor diagnostika AG, Germany).
Exosome Isolation, Identification and RNA
Extraction
A total of 3-4mL of serum was mixed with RiboTM Exosome
Isolation Reagent (RiboBio, China) for exosome extraction. The
presence and purity of exosomes were assessed by nanoparticle
tracking analysis (NTA) and transmission electron microscopy
(TEM). To determine the exosome concentration, the exosomal
marker proteins CD63 and CD81 were labeled with monoclonal
antibodies (BD Biosciences, USA) and analyzed by a BD
Accuri C6 flow cytometer (BD Biosciences, USA). The exosome
size was assessed by a ZETASIZER Nano SeriesNano-ZS
(Malvern Instruments, Ltd., UK). Exosomes were processed for
visualization by TECNAI 12 TEM System (Philips, Netherlands).
Total exosomal RNAwas extracted using aHiPure Serum/Plasma
miRNA Kit (Magen, China) according to the manufacturer’s
protocol. After isolation, RNA quantification and purity were
assessed by a Qubit 2.0 (Life Technologies, USA) and an Agilent
2200 TapeStation (Agilent Technologies, USA).
Library Construction and Next-Generation
Sequencing
Approximately 100 ng of total RNA per sample was used to
construct a library using an NEBNext R© Multiplex Small RNA
Library Prep Set for Illumina R© (Illumina, USA) and only small
RNAs less than 30 nt were used for library preparation. RNA was
qualified and was then amplified and sequenced using a HiSeq
Rapid SBS Kit V2 (50 cycles) and a HiSeq Rapid SR Cluster Kit
V2 on a HiSeqTM 2500 platform (Illumina, USA).
Validating by RT-qPCR
To validate the NGS results, we selected potential miRNAs for
further analysis by RT-qPCR in another cohort of participants.
The selected miRNAs should have different expressions between
the acute phase and remission phase. Quantification of miRNAs
expression was performed using a miRNA qPCR Starter Kit
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(RiboBio, China) on a C1000 TouchTM Sequence Detection
System (Bio-Rad, USA) according to the manufacturer’s
protocols. We chose the cel-miR-39-3p mimic, which has a stable
expression between cells and exosomes, to normalize technical
variation between the samples.
Target Prediction and Functional Analysis
In this study, we used the miRDeep algorithm to match raw NGS
reads to miRNAs. Subsequent calculations were performed by
using the R statistical programming environment (version 3.0.2).
To increase the comparability of the raw read counts from NGS,
standard quantile normalization was used as implemented in the
normalize-counts per million functions. We used four widely
accepted databases to predict the mutual potential target genes
of the candidate miRNAs: TargetScan (http://www.targetscan.
org/vert_72/), miRDB (http://mirdb.org/), DIANA tools microT-
CDS (http://diana.imis.athena-innovation.gr/DianaTools/) and
miRDIP (http://ophid.utoronto.ca/mirDIP/). The target genes
predicted by all four databases were selected for further biological
function analysis and Kyoto Encyclopedia of Genes andGenomes
(KEGG) pathway analysis by the Database for Annotation,
Visualization and Integrated Discovery (DAVID) Bioinformatics
Resources 6.8 (https://david.ncifcrf.gov/) and the Search Tool
for Retrieval of Interacting Genes/Proteins (STRING) database
v11.0 (https://string-db.org/).
Statistical Analysis
The sex distribution among the groups was assessed by a 2
x 3 or 2 x 2 Chi-square test. Age differences between groups
were assessed by analysis of variance. For clinical data, p values
of < 0.05 were considered significant. The edgeR generalized
linear model approach (version 3.22.5) was applied to determine
differential expression between groups using log (counts per
million) normalization. False discovery rate (FDR) adjustment
was performed to account for multiple testing. To reduce the
false positive rate, genes with an adjusted two-sided P-value of




In the NGS study, a total of 52 NMOSD patients (17 in the acute
phase and 35 in remission), 18 RRMS patients (6 in the acute
phase and 12 in remission) were consecutively included. There
were significant differences in the mean age and sex distributions
among the three groups (p = 0.001 and p = 0.010, respectively),
which was in accordance with the clinical characteristics (12).
There’s no difference in the proportion of patients who received
immunotherapy between NMOSD and MS patients during this
study (p = 0.188). The steroids dosage of patients included in
the study was 8mg methylprednisolone per day. There was no
significant difference in the EDSS score between patients with
NMOSD and MS, whereas patients in the acute stage scored
higher than those in remission. Five MS patients were oligoclonal
bands positive which was higher than NMOSD (p < 0.001). The
clinical characteristics of participants in the NGS study were
shown in Table 1.
In the RT-qPCR validation study, a separate cohort of 31
NMOSD patients (16 in the acute phase and 15 in remission)
and 14 HCs were included to validate the results of the NGS
study. There was no significant difference in the sex distribution,
mean age or disease duration among the groups. The median
TABLE 1 | Clinical characteristics of the patients with NMOSD, RRMS and HCs in
the NGS study.
NMOSD (n = 52) RRMS (n = 18) HCs (n = 17) p
Mean age at
onset (range, y)
37.9(19–63) 26.8(14–53) 32.8(13–61) 0.001
Females/males
(% female)




45.5(2–186) 33.5(3-100) – 0.018
Median EDSS
scores (range)
3.0(0–8.0) 2.5(0–7.5) – 0.466
Positive rate of
OCBs (%)















NMOSD, neuromyelitis optica spectrum disorders; RRMS, relapsing-remitting multiple
sclerosis; HCs, healthy controls; NGS, next-generation sequencing; y, years; mo, month;
EDSS, expanded disability status scale; OCBs, oligoclonal bands; AZA, azathioprine;
MMF, mycophenolate mofetil; S, steroids.








HCs (n = 14) p
Mean age at
onset (range, y)
37.2(20–61) 38.6(21–60) 35.43(21–58) 0.751
Females/males
(% female)




44(13–177) 47(24–134) – 0.692
Median EDSS
scores (range)















NMOSD, neuromyelitis optica spectrum disorders; HCs, healthy controls; RT-qPCR,
realtime quantitative polymerase chain; y, years; mo, month; EDSS, expanded disability
status scale; AZA, azathioprine; MMF, mycophenolate mofetil; S, steroids.
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FIGURE 1 | Analysis of serum exosomal miRNAs in NMOSD, MS and HCs by next-generation sequencing. (A) Transmission electron microscopy images of extracted
serum exosome. The diameter of typical exosome is <100 nm. (B) The representative result of nanoparticle tracking analysis. (C) Two exosomal markers (CD63 and
CD81) detected by flow cytometry. (D) The mean sequencing count and the mean read count per sample of different classes of RNA in NMOSD, MS, and HCs.
EDSS score of acute NMOSD patients was higher than that of
remitting NMOSD patients. The clinical characteristics of 31
NMOSD patients and 14HCs were shown inTable 2. In addition,
serum samples during the acute and remitting stage were taken
from each NMOSD patients (5 females and 2 males), in order
to conduct a longitudinal study. The mean age at onset was 34.7
(22–57), median disease duration was 48 (18–155) months. The
median EDSS scores was 5.0 (3-7) in the acute stage, which was
higher than 2.0 (1-3) in the remission stage.
Exosome Isolation and Characterization
To assess the quality of exosomes, we randomly selected
8 samples for exosome assessment by TEM and NTA.
TEM revealed typical rounded and membrane-bound
particles with a homogeneous appearance (Figure 1).
No morphological differences were observed between
the particles from the three groups. In addition, NTA
revealed that the size distribution of the exosomes ranged
from 30 to 150 nm for all participants. Flow cytometry
revealed that the average positive rates of CD63 and
CD81 expression were 60.2 and 61.0%, respectively. These
results indicated that the particles isolated from serum were
qualified exosomes.
Exosomal miRNAs Profile in Serum
To investigate the exosomal miRNAs profile in NMOSD, we
carried out exosomal miRNAs sequencing. Interestingly,
this study found different exosomal miRNAs profile in
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TABLE 3 | Different exosomal miRNAs profile in NMOSD compared with HCs.
NMOSD relapse vs. HCs NMOSD remission vs. HCs NMOSD relapse vs. remission
miRNA Log2FC FDR miRNA logF2C FDR miRNA Log2FC FDR
hsa-miR-122-3p 6.72 0.00002 hsa-miR-4424 −3.20 0.00020 hsa-miR-194-3p 2.76 0.00000
hsa-miR-5589-3p 4.78 0.00195 hsa-miR-6764-3p −2.90 0.00023 hsa-miR-200a-5p 2.22 0.00001
hsa-miR-455-3p 4.60 0.00252 hsa-miR-412-3p −3.00 0.00055 hsa-miR-122-3p 4.12 0.00001
hsa-miR-548ah-5p 3.57 0.00923 hsa-miR-376c-5p −3.21 0.00102 hsa-miR-455-3p 4.00 0.00008
hsa-miR-194-3p 3.17 0.00007 hsa-miR-376b-5p −3.21 0.00102 hsa-miR-455-5p 2.32 0.00122
hsa-miR-105-5p 2.91 0.00796 hsa-miR-758-3p −1.80 0.00482 hsa-miR-574-3p 1.16 0.00281
hsa-miR-200a-5p 2.75 0.00002 hsa-miR-409-5p −1.72 0.00620 hsa-miR-3130-5p 2.16 0.00829
hsa-miR-4712-3p 2.67 0.00923 hsa-miR-23b-3p 1.32 0.00965
hsa-miR-455-5p 2.59 0.00514 hsa-miR-3065-5p 2.27 0.00979
hsa-miR-192-5p 1.52 0.00721 hsa-miR-223-3p 1.55 0.00979
hsa-miR-574-3p 1.33 0.00514 hsa-miR-493-5p 1.40 0.00979
hsa-miR-27b-3p 1.32 0.00923 hsa-miR-30a-3p 1.19 0.00979
hsa-miR-6774-3p −2.70 0.00514 hsa-miR-6774-3p −2.27 0.00979
hsa-miR-6764-3p −2.90 0.00307 hsa-miR-186-3p −2.27 0.00979
hsa-miR-412-3p −3.00 0.00514 hsa-miR-572 −2.28 0.00979
hsa-miR-518f-5p −3.17 0.00514 hsa-miR-3156-5p −2.32 0.00979
hsa-miR-526a-5p −3.17 0.00514 hsa-miR-5684 −2.41 0.00979
hsa-miR-520c-5p −3.17 0.00514
hsa-miR-518d-5p −3.17 0.00514
NMOSD (Table 3). Four miRNAs exhibited significantly
altered expression in NMOSD compared with that in HCs.
Hsa-miR-122-3p was upregulated and hsa-miR-4424, hsa-
miR-6764-3p and hsa-miR-412-3p were downregulated in
patients with NMOSD relative to their expression in HCs.
Nineteen miRNAs were found differentially expressed in acute
NMOSD patients compared with HCs. In the comparison
of acute with remitting NMOSD, we found 17 significantly
differentially expressed miRNAs. In addition, 7 miRNAs were
downregulated in remitting NMOSD patients compared with
HCs (Figure 2).
Among the differentially expressed miRNAs, hsa-miR-122-3p
and hsa-miR-200a-5p had an average of∼100 reads in patients in
the acute phase. In addition, hsa-miR-122-3p and hsa-miR-200a-
5p were upregulated in acute NMOSD relative to their expression
in patients with remitting NMOSD and HCs, with > 2-fold
changes and significant differences.
This study also enrolled 6 acute and 12 remitting MS patients
for comparison with NMOSD patients and HCs. However, no
miRNA was found to be differentially expressed between MS
group and NMOSD group or HCs. No difference was found
between the acute MS and remitting MS or HCs. When we
compared remitting MS with HCs, we found that hsa-miR-
582-3p and hsa-miR-542-3p were upregulated in remitting MS
patients. Finally, we compared the exosomal miRNA expression
profile of NMOSD with that of MS. We found that miR-
320a-5p was significantly downregulated in acute NMOSD
relative to its expression in acute MS. Six miRNAs were also
downregulated in remitting NMOSD relative to their expression
in remitting MS, that were hsa-miR-380-3p, hsa-miR-3145-3p,
hsa-miR-216a-5p, hsa-miR-548ba, hsa-miR-153-3p, hsa-miR-
448 (Table 4).
Based on the results shown above, we found evidence
that exosomal miRNAs were differentially expressed between
NMOSD and MS or HCs. Hsa-miR-122-3p and hsa-miR-
200a-5p were most abundant and valuable in distinguishing
NMOSD relapse.
RT-qPCR Validation
In this part of study, hsa-miR-122-3p and hsa-miR-200a-5p were
screened as candidates for further validation. We did not recruit
MS patients in this part of the study because of the limited
findings in the NGS study of MS. Hsa-miR-194-3p and hsa-miR-
455-3p were not selected for validation due to the low expression
in the serum exosome.
The RT-qPCR results revealed the same trend as the
NGS data. According to the expression of hsa-miR-122-
3p was significantly higher in relapsing than in remitting
NMOSD or HCs (p = 0.004 and p = 0.012, respectively).
The mean expression level of hsa-miR-122-3p was higher in
HCs than in remitting NMOSD patients, but the difference
was not significant (p = 0.058). Hsa-miR-200a-5p was also
significantly overexpressed in relapsing NMOSD compared
with remitting NMOSD (p = 0.023). However, no significant
differences were found between NMOSD subgroups and HCs
(Figure 3A).
In addition, the longitudinal study demonstrated that the
expressions of hsa-miRNA-122-3p and hsa-miRNA-200a-5p
were higher in relapsing than in remitting NMOSD patients (p
< 0.001 and p= 0.007, respectively) (Figure 3B).
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FIGURE 2 | Volcano plots demonstrated different exosomal miRNAs profiles between NMOSD and HCs based on the NGS data. (A) The comparation of exosomal
miRNAs profiles in NMOSD patients compared with HCs. (B,C) The comparations of exosomal miRNAs profiles between the subgroups of NMOSD and HCs. (D) The
comparations of exosomal miRNAs profiles between relapsing NMOSD patients and remitting NMOSD patients. Non-DE, not differentially expressed.
Correlations Between miRNAs Expression
and Clinical Characteristics
Hsa-miR-122-3p and hsa-miR-200a-5p were selected to analyse
the correlation between miRNAs and clinical characteristics.
Interestingly, we found that the expressions of hsa-miR-122-3p
and hsa-miR-200a-5p had positive correlations with EDSS scores
for all NMOSD patients (R = 0.47, p = 0.0082 and R = 0.43,
p = 0.0152) according to the RT-qPCR data (Figure 3C). The
correlation of hsa-miR-122-3p expression with EDSS score was
also proved by the NSG data (R = 0.40, p = 0.0029). However,
no correlation of hsa-miR-200a-5p was found according to the
NGS study (R = 0.24, p = 0.089). No correlations between
EDSS scores and the expressions of hsa-miRNA-122-3p and hsa-
miRNA-200a-5p in relapsing NMOSD patients were found based
on the RT-qPCR data (R = 0.175, p = 0.517, and R = 0.234,
p = 0.384, respectively). The expressions of hsa-miRNA-122-3p
and hsa-miRNA-200a-5p were not significantly different between
NMOSD patients with attacks in the spinal cord and in the
optic nerves, based on the NGS study (p = 0.158 and p =
0.279, respectively) and the RT-qPCR study (p = 0.231 and p
= 0.392, respectively). No correlation was found between the
selected miRNAs and age, gender, disease course, number of
attacks or oligoclonal bands status. In addition, no significant
difference was found between NMOSD patients with or without
receiving steroids according to the NGS data (p = 0.752 and p
= 0.129, respectively) or the RT-qPCR data (p = 0.633 and p =
0.252, respectively).
Gene Target Prediction and Pathway
Analysis
These four miRNAs databases (13–16) revealed 22 overlapping
target genes for hsa-miR-122-3p and 365 overlapping target genes
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for hsa-miR-200a-5p. KEGGpathway analysis of hsa-miR-122-3p
by DAVID and STRING both indicated enrichment of mitogen-
activated protein kinase (MAPK) signaling pathway, with four
genes involved. Regarding hsa-miR-200a-5p, KEGG pathway
TABLE 4 | Different exosomal miRNAs expressions in MS compared with NMOSD
and HCs.
miRNA Log2FC FDR
MS remission vs. HCs hsa-miR-582-3p 2.68 0.00248
hsa-miR-542-3p 2.42 0.00248
NMOSD relapse vs. MS relapse hsa-miR-320a-5p −4.16 0.00020






analysis revealed 5 enriched pathways, including regulating
pluripotency of stem cells (p = 0.013), pathways in cancer (p
= 0.020), Ras signaling pathway (p = 0.038), and Wnt signaling
pathway (p= 0.043) (Figure 4). However, no KEGG pathway was
enriched by STRING database.
DISCUSSION
In this study, we report a different serum exosomal miRNAs
profile in patients with NMOSD compared with that in MS or
HCs. During the identification of exosomal RNA, we identified
34 different classes of RNA, including miRNA, ribosomal RNA,
small nucleolar RNA, long non-coding RNA, retained introns,
small nuclear RNA, mitochondrial transfer RNA, pseudogenes
and other RNAs. The key findings of this study were as follows:
(i) the NGS RNA-sequence data revealed an miRNA pattern
in patients with NMOSD different from that in HCs; (ii) hsa-
miR-122-3p and hsa-miR-200a-5p were significantly upregulated
in acute NMOSD relative to their levels in remission, the
FIGURE 3 | The validation of potential exosomal miRNAs by RT-qPCR and the correlation of miRNAs with EDSS scores. (A) The RT-qPCR validation demonstrated
that the expressions of hsa-miRNA-122-3p and hsa-miRNA-200a-5p were significantly higher in relapsing NMOSD than in remission. (B) The longitudinal study
demonstrated that the expressions of hsa-miRNA-122-3p and hsa-miRNA-200a-5p were higher in relapsing than in remitting NMOSD patients. (C) The analysis
showed that the expressions of hsa-miR-122-3p and hsa-miR-200a-5p were positively correlated with EDSS scores of NMOSD patients based on the RT-qPCR data.
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FIGURE 4 | The possible signaling pathways of hsa-miRNA-122-3p and hsa-miRNA-200a-5p enriched by the KEGG pathway analyses. The genes with yellow
backgrounds are the target genes of hsa-miRNA-122-3p and hsa-miRNA-200a-5p.
expressions were age- and sex-independent (17, 18); (iii) hsa-
miR-122-3p had a positive correlation with the EDSS score in
NMOSD and MS; and (iv) the MAPK, Wnt and Ras signaling
pathways, which might participate in immunoregulation in
NMOSD pathogenesis, were found to be enriched in the
biological function analysis.
MiR-122-3p is a product of miR-122, serum exosomal hsa-
miR-122-3p was found to be upregulated in chronic atrophic
gastritis and could be a promising diagnostic biomarker (19).
MiR-122-3p expression was also found to be decreased in the
plasma of patients with rheumatoid arthritis (20). A study on
MS demonstrated that the level of serum exosomal hsa-miR-
122-3p was significantly decreased in relapsing MS patients
compared with that in patients in remission and controls (8).
In this study, our data demonstrated that the level of exosomal
hsa-miR-122-3p was increased in the serum of acute NMOSD
patients compared with that in remitting patients and HCs.
Exosomal hsa-miR-122-3p expression correlated with the EDSS
score, indicating that serum exosomal hsa-miR-122-3p might
indicate NMOSD relapse.
MiR-200a-5p is one of the products of miR-200a, which
is involved in various autoimmune diseases. Hsa-miR-200a
expression was higher in CD4+ T cells from patients with
relapsing MS than in those of remitting MS and HCs. Molecular
signaling pathway enrichment analysis revealed that miR-200a
might induce T helper 17 cell differentiation via the Janus kinase-
signal transducer and activator of transcription, transforming
growth factor-β and mammalian target of rapamycin pathways
(21). A study revealed that hsa-miR-200a expression was
significantly decreased in patients with rituximab-treated NMO,
with a fold change of 0.21 relative to that in untreated patients
(22). However, no expression difference of hsa-miR-122-3p and
hsa-miR-200a-5p in the serum and whole blood was found
between NMOSD and HCs (4). In this study, we found that
hsa-miR-200a-5p expression was significantly elevated in patients
with acute NMOSD compared with that in NMOSD in remission.
To better understand the consequences of hsa-miR-122-3p
and hsa-miR-200a-5p dysregulation, we searched their target
genes and analyzed their potential biological functions. The
functional annotation revealed that the targets of hsa-miR-
122-3p were related to the immunoglobulin domain terms.
Four target genes of hsa-miR-122-3p were involved in the
MAPK signaling pathway. The MAPK signaling pathway is
widely involved in disorders of the innate and adaptive immune
systems (23). This study revealed that the Ras signaling
pathway and Wnt signaling pathway were enriched based
on the target genes of hsa-miR-200a-5p. The Ras signaling
pathway has multiple modulatory effects on cell proliferation
and inflammatory responses. Altered Ras expression in T
lymphocytes can result in autoimmune disorders such as
systemic lupus erythematosus (24).
Several limitations of our study should be noted. Firstly, the
number of RRMS patients included in the NGS study was small,
we didn’t find valuable dysregulated miRNAs in RRMS patients
compared with HCs. This result might also be caused by different
disease-modifying therapies in RRMS patients. Secondly, this
study did not conduct research on the precise origin and potential
target of the exosome and miRNAs. Therefore, it is difficult to
define the specific destinations and biological function of the
exosomal miRNAs. Further study on larger samples should be
performed to validate our results, and focused on the precise
mechanisms of exosomes and dysregulated exosomal miRNAs.
CONCLUSION
In summary, our study demonstrated that profile of miRNAs
delivered by exosomes in NMOSD with seropositive AQP4-IgG
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was different from that in MS or HCs. Exosomal microRNAs
could be applied as potential biomarkers for NMOSD.
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